Sign up to save your podcasts
Or
Share AI Access Brief Podcast
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
AI Access Brief Podcast
AI Access Brief Podcast episodes
- CMS Star Ratings, NICE Digital Health, EU Oncology JCAsEpisode 153 — 29 October 2026CMS overhauls Star Ratings methodology, NICE advances digital health assessment, EU launches oncology JCAs, and FDA expands RWE use for rare diseases.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast10 min
- US Access Erosion & Pricing SignalsEpisode 152 — 28 October 2026Examining HCA's profit warning as a bellwether for US healthcare access erosion, analyzing subcutaneous Leqembi's HEOR implications, and dissecting the FTC-CVS insulin settlement's impact on PBM practices.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast8 min
- Leqembi SubQ, FTC Insulin, ICER Advice, HCA WarningEpisode 151 — 27 October 2026FDA approves subcutaneous Leqembi; FTC settles insulin pricing case; ICER expands early-phase advice; HCA profit warning flags US access challenges.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast10 min
- US Healthcare Access & Value ShiftsEpisode 150 — 26 October 2026Examining US healthcare access erosion, Alzheimer's treatment evolution, PBM pricing practices, and early-phase evidence strategy reshaping.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast12 min
- HTA Evidence Evolution & IRA ImpactEpisode 149 — 25 October 2026Examining evolving HTA evidence frameworks, IRA implications for evidence strategies, patient-centered endpoint integration, and gene therapy cost-effectiveness hurdles.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast7 min
- Access Erosion Signals & New PathwaysEpisode 148 — 24 October 2026Examining systemic access challenges, novel Alzheimer's administration shifts, PBM reform implications, and early HEOR integration in development.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast8 min
- HTA Frameworks & Pricing PressuresEpisode 147 — 23 October 2026Examining operational hurdles in CMS Part D redesign, evolving FDA RWE guidance, NICE's RWE framework updates, and the first wave of oncology JCAs under EU HTA.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast9 min
- HCA Warning, Leqembi SubQ, FTC Insulin, ICER AdviceEpisode 146 — 22 October 2026HCA's profit warning signals US healthcare access erosion; subcutaneous Leqembi approval transforms Alzheimer's value evidence; FTC-CVS insulin settlement exposes PBM pricing practices; ICER expands early-phase scientific advice to align development with HTA needs.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast8 min
- HTA Evolution & Market AccessEpisode 145 — 21 October 2026Examining evolving HTA frameworks across emerging markets and digital health evidence integration challenges.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast11 min
- Profit Warning, Leqembi, Insulin, ICEREpisode 144 — 20 October 2026Examining HCA's access crisis, subcutaneous Leqembi's value shift, insulin pricing reforms, and ICER's evidence strategy evolution.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast6 min
About AI Access Brief Podcast
From the publisher's feed
AI Generated Daily briefings on HEOR, HTA strategy and the evidence access landscape. For pharmaceutical and biotech professionals navigating regulatory-payer alignment, HTA submissions, and…
evidence strategy.